购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

CP671305

Rating icon 很棒
产品编号 T4695Cas号 445295-04-5

CP671305 是口服具有活力的 phosphodiesterase-4-D 选择性抑制剂,具有很高的活性。

CP671305
TargetMol

为众多的药物研发团队赋能,

让新药发现更简单!

CP671305

Rating icon 很棒
纯度: 99.22%
产品编号 T4695Cas号 445295-04-5

CP671305 是口服具有活力的 phosphodiesterase-4-D 选择性抑制剂,具有很高的活性。

规格价格库存数量
1 mg¥ 683现货
5 mg¥ 1,660现货
10 mg¥ 2,490现货
25 mg¥ 4,160现货
50 mg¥ 5,880现货
100 mg¥ 7,930现货
1 mL x 10 mM (in DMSO)¥ 1,680现货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多

"CP671305"的相关化合物库

选择批次:
纯度:99.22%
联系我们获取更多批次信息
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
CP671305 is an orally active, potent and selective inhibitor of phosphodiesterase-4-D.
体外活性
CP-671,305 is a substrate of human OATP2B1 with a high affinity (Km=4 μM) but not a substrate for human OATP1B1 or OATP1B3. CP-671,305 is identified as a substrate of MRP2 and BCRP, but not MDR1. CP-671,305 displays high affinity (Km=12 μM) for rat hepatic Oatp1a4. CP-671,305 does not exhibit competitive inhibition of the five major cytochrome P450 enzymes, namely CYP1A2, 2C9, 2C19, 2D6 and 3A4 (IC50s >?50 μM). Likewise, no time-dependent inactivation of the five major cytochrome P450 enzymes is discernible with CP-671,305.
体内活性
The pharmacokinetics of CP-671,305 are largely unaltered, and compromised biliary clearance of CP-671,305 is compensated by increased urinary clearance. CP-671,305 demonstrates generally favourable pharmacokinetic properties, systemic plasma clearance after intravenous administration is low in Sprague-Dawley rats (9.60?±?1.16?mL/min/kg), beagle dogs (2.90?±?0.81?mL/min/kg) and cynomolgus monkeys (2.94?±?0.87?mL/min/kg) resulting in plasma half-lives >?5?h. Moderate to high bioavailability in rats (43-80%), dogs (45%) and monkeys (26%) is observed after oral dosing. In rats, oral pharmacokinetics are dose dependent over the dose range studied (10 and 25?mg/kg).
动物实验
Jugular vein cannulated and bile duct-exteriorized male Sprague-Dawley rats (230-250 g) are used in the assay. All animals are fasted overnight before dosing, whereas access to water is provided ad libitum. Animals are fed following collection of the 2-h blood samples. CP-671,305 (3 mg/kg) in glycerol formal is administered intravenously (i.v.) via the jugular vein to three rats over 30 s, and serial plasma samples are collected before dosing and 0.033, 0.15, 0.5, 1, 2, 4, 6, 8, and 24 h after dosing. All plasma samples are kept frozen until analysis. In addition, an i.v. dose of 3 mg/kg is also given to bile duct-exteriorized rats (n=3), where plasma, bile, and urine samples are collected on ice for up to 24 h and stored at -20°C until analysis. For the DDI studies, cyclosporin A (20 mg/kg in glycerol formal) is administered i.v. 30 min before intravenous administration of CP-671,305. Rifampicin (50 mg/kg) in saline is administered i.v. 5 min before the administration of CP-671,305. Plasma samples from the various pharmacokinetic studies are generated by centrifugation at 3000 rpm for 10 min at 4°C. Samples are stored at -20°C, pending analysis by LC-MS/MS.
化学信息
分子量454.4
分子式C23H19FN2O7
CAS No.445295-04-5
SmilesC[C@@H](Oc1ccc(CNC(=O)c2cccnc2Oc2ccc3OCOc3c2)c(F)c1)C(O)=O
密度no data available
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
DMSO: > 150 mg/mL (330.11 mM)
溶液配制表
1mg5mg10mg50mg
1 mM2.2007 mL11.0035 mL22.0070 mL110.0352 mL
5 mM0.4401 mL2.2007 mL4.4014 mL22.0070 mL
10 mM0.2201 mL1.1004 mL2.2007 mL11.0035 mL
20 mM0.1100 mL0.5502 mL1.1004 mL5.5018 mL
50 mM0.0440 mL0.2201 mL0.4401 mL2.2007 mL
100 mM0.0220 mL0.1100 mL0.2201 mL1.1004 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

Related Tags: buy CP671305 | purchase CP671305 | CP671305 cost | order CP671305 | CP671305 chemical structure | CP671305 in vivo | CP671305 in vitro | CP671305 formula | CP671305 molecular weight